A Phase I Clinical Study to Evaluate the Safety of PCV26 in Individuals ≥60

NCT06970756 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Pneumococcal Diseases

Interventions

BIOLOGICAL: 26-valent Pneumococcal Conjugate Vaccine
BIOLOGICAL: 13-valent Pneumococcal Conjugate Vaccine

Sponsor

Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd